Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year

• Status: Completed
• Trial end date: 2018-07-26
• Target enrollment: 0
• Participant gender: All

Summary

This multicenter, prospective, non-interventional study is designed to obtain an accurate estimation of the drug retention rate of Tocilizumab (TCZ) Subcutaneously (SC) under real-world conditions in participants with moderate to severe rheumatoid arthritis (RA).

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Methotrexate

Criteria

Inclusion Criteria:

• Participants at least 18 years old

• Participants with moderate to severe RA not previously treated with TCZ (Intravenous [IV] or SC) for whom the rheumatologists have decided to initiate TCZ SC treatment as monotherapy or in combination with another conventional synthetic disease modifying anti-rheumatic drugs (csDMARD)

Exclusion Criteria:

• Participants taking part in a clinical trial on RA at the time of inclusion

• Participants with a contra-indication to TCZ SC therapy